Ocular Allergy Treatment Practical Impact Trial

• Status: Unknown status
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Starx Research Center, LLC
• Treatments: Alcaftadine

Criteria

Inclusion Criteria:

1. patients age 18 and older with a history of seasonal or perennial forms of allergic conjunctivitis and skin test positive reactivity to seasonal aeroallergens

2. Total Ocular Symptom Score (TOSS) on the day of enrollment of 4 or more.

3. have allergic ocular symptoms for the past week for which they are either treating with ophthalmic agents or have had no treatment.

4. Are willing/able to follow instructions from the study investigator and his/her study staff.

5. Have signed infromed consent approved by Institutional Review Board or Independent Ethics Committee.

-

Exclusion Criteria:

1. Active ocular infection;

2. History of retinal detachment, diabetic neuropathy, or any progressive retinal disease;

3. Ocular surgical intervention within three (3) months prior to visit 1 or scheduled during the study.

4. History of unstable, or uncontrolled disease of any nature.

5. Pregnancy or lactation;

6. Have a known hypersensitivity tp LASTACAFT™ (alcaftadine) -